Skip to main content
Figure 1 | Orphanet Journal of Rare Diseases

Figure 1

From: Comprehensive characterization of malignant phyllodes tumor by whole genomic and proteomic analysis: biological implications for targeted therapy opportunities

Figure 1

Imaging studies, histopathology and FISH studies: UA and B: CT of the chest showing metastatic masses in the lung. C Hematoxylin and Eosin stained section of the tumor from the right mastectomy shows a malignant sarcoma/malignant phyllodes tumor that has high stromal cellularity and a mitotic index of 11 per 10 high power fields. D HER-2/neu by Fluorescence in Situ Hybridization (FISH) HER-2 gene amplification was assessed utilizing the PathVysion assay (Vysis Corp., Downers Grove, Illinois). The identification probes for the HER-2 (SpectrumOrange) and alpha satellite DNA sequence at the centromeric region of chromosome 17 (SpectrumGreen) were hybridized according to the manufacturer’s guidelines. At least twenty non-overlapping nuclei containing at least one orange and one green signal were enumerated. The ratio of orange signals (HER-2 gene) to green signals (chromosome 17) was calculated. A ratio greater than or equal to 2.0 is considered as amplified based on the FDA approval in this kit. The CAP HER-2 consensus conference 2002 suggested that a ratio of 1.8-2.2 be considered as borderline.

Back to article page